Open report — full analysis, no account required.

Sign up to generate reports and read filings that aren't on the open list.

Sign up free

Get notified when TPST files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: TPST Tempest Therapeutics, Inc. 8-K

Tempest Therapeutics reports Q1 2026 financial results

Filed May 14, 2026 · Period ending May 14, 2026 · ~1 min read

2 key changes 2 sections

Key Changes

  • medium

    Company announced financial results for the quarter ended March 31, 2026, along with business highlights. Specific figures are in the attached press release not included in the 8-K filing text.

  • low

    This is a routine quarterly earnings disclosure filed via 8-K with press release attachment. No unusual events or material business changes disclosed in the filing body.

    8-K: Earnings view on EDGAR →

Summary

Tempest Therapeutics filed its routine quarterly earnings 8-K announcing first quarter 2026 financial results for the period ending March 31, 2026. The filing itself contains minimal detail, with the actual financial figures and business updates contained in an attached press release (Exhibit 99.1) that is not reproduced in the 8-K body text. For retail investors, this is a standard quarterly disclosure with no red flags or unusual elements.

The filing provides no insight into the actual financial performance or business developments without access to the press release. Investors should review the full press release on the company's investor relations website or SEC EDGAR to understand Q1 performance, cash position, and any pipeline updates. Watch for the upcoming 10-Q filing, which will provide complete financial statements and management discussion of quarterly results.

Section-by-Section Diff

Event · Item 2.02 — Results of Operations and Financial Condition

~100 words

Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.

1 Added
Added Q1 2026 financial results medium

Added in current filing · verify on EDGAR →

On May 14, 2026, Tempest Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026 and other business highlights.

The company disclosed its financial results for the first quarter of 2026 ending March 31, 2026, along with other business highlights. The actual financial figures and business updates are contained in the attached press release (Exhibit 99.1), which is not included in this 8-K body text.

Event · Item 9.01 — Financial Statements and Exhibits

~100 words

Item 9.01 — Financial Statements and Exhibits filed; see Key Changes for terms.

1 Added
Added Press release attachment medium

Added in current filing · verify on EDGAR →

99.1 Press release dated May 14, 2026

The company attached a press release dated May 14, 2026 as Exhibit 99.1. The 8-K body does not describe the content of the press release, so the nature of the disclosure cannot be determined from this filing alone.

Was this report useful?

Figures/quotes linked to EDGAR · Narrative written by AI · May 25, 2026 · How we verify